Last reviewed · How we verify
hFSH-HP
At a glance
| Generic name | hFSH-HP |
|---|---|
| Also known as | Fostipur |
| Sponsor | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Type of Gonadotropin and Embryo Kinetics of Development (PHASE4)
- Elonva in Combination With Hp-FSH Versus Elonva With Low Dose hCG (PHASE4)
- FSH Followed by HMG vs FSH Plus HMG in IVF (PHASE4)
- N680S Polymorphism of the FSHR Gene and Its Relationship With the Type of Gonadotropin Used in COS
- Study to Compare hFSH-HP (Fostipur) and hMG-HP(Meriofert) in Patients With Polycystic Ovary Under a IVF/ICSI Cycle. (PHASE4)
- Corifollitropin Alfa Followed by Menotropin for Poor Ovarian Responders Trial (PHASE3)
- Use of Corifolitropin Alfa in Oocyte Donors (PHASE4)
- Menopur Mixed Protocol (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- hFSH-HP CI brief — competitive landscape report
- hFSH-HP updates RSS · CI watch RSS
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau portfolio CI